Educational reference, not medical advice. This page summarizes information from published research and regulatory filings for educational purposes. It is not a recommendation to use any compound and should not replace guidance from a licensed healthcare provider. Most peptides discussed here are not approved for the uses described.
What it is
Klow Blend is a commercial pre-mixed combination of four peptides — BPC-157, GHK-Cu, TB-500, and KPV — co-lyophilized in a single vial. It extends the three-component Glow Blend by adding KPV, the C-terminal tripeptide of α-melanocyte-stimulating hormone, which has been studied in rodent models for inflammatory bowel disease.
The product is marketed in research-peptide channels for "anti-inflammatory and healing" protocols. As with all multi-peptide commercial blends, the combination itself has not been evaluated in any clinical study. Each component has its own research base; the four-way mixture does not.
History
The Klow name appeared in research-peptide retail in the early 2020s as a derivative of the older three-peptide Glow Blend, marketed to capture the additional anti-inflammatory profile that the α-MSH fragment KPV is reported to add. There is no academic publication describing the four-peptide preparation, no pharmacokinetic study of the mixed product, and no published rationale for the ratios used.
Component histories:
- BPC-157 — Sikiric lab, University of Zagreb, 1991.
- GHK-Cu — Pickart lab, UCSF, 1973.
- TB-500 — 17–23 fragment of Thymosin Beta-4, characterized in the 2000s.
- KPV — α-MSH(11-13), characterized as the anti-inflammatory active fragment of α-MSH in the late 1990s.
Regulatory status
Klow Blend has no regulatory approval. None of the four components is approved as an injectable drug in the United States. BPC-157 is in FDA 503A Category 2, restricting compounding. GHK-Cu is approved only as a topical cosmetic. TB-500 is WADA-prohibited. KPV has no approval for any therapeutic use. The blend is sold through research-chemical suppliers labeled for laboratory use only.
How researchers describe its action
Because the four-peptide combination has not been studied as a unit, the described mechanism is the sum of what is known about each component:
- BPC-157 is described in preclinical work as a modulator of nitric oxide signaling and an enhancer of VEGFR2 expression.
- GHK-Cu is documented as a stimulator of collagen and elastin synthesis and a copper carrier for lysyl oxidase, primarily in topical and cell-culture studies.
- TB-500 carries the actin-binding sequence of Thymosin Beta-4 and is described as a promoter of cell migration.
- KPV is described as a suppressor of NF-κB signaling in macrophages and intestinal epithelium, with secondary antimicrobial activity in vitro.
Interactions between the four peptides — whether kinetic, pharmacological, or otherwise — have not been studied.
Half-life and dosing intervals
The component half-lives span a wide range:
- KPV: approximately 20–30 minutes.
- BPC-157: 15–30 minutes.
- GHK-Cu: 30–60 minutes.
- TB-500: 1.5–3 hours.
Observational protocols circulated in research-peptide channels typically describe subcutaneous injection once daily, with the total per-injection mass in the 1–3 mg range across all four peptides. These regimens are not derived from any controlled human trial.
Reconstitution example
Klow Blend is commonly supplied as an 80 mg lyophilized vial containing all four peptides at supplier-defined ratios. Reconstituted with 2 mL of bacteriostatic water, the total peptide concentration is 40 mg/mL. On a 1 mL U-100 insulin syringe, 5 units (0.05 mL) contains approximately 2 mg of total peptide mass, divided across the four components according to the supplier's specification.
Vial's calculator can compute total mass per injection unit; per-component mass depends on the ratio printed by the manufacturer, which is generally not independently verified.
What to know
- No combined clinical data. The four-peptide blend has never been studied as a single product. All evidence applies to individual components in isolation.
- Component regulatory status. BPC-157 is restricted by the FDA from US compounding; GHK-Cu is approved only as a topical cosmetic; TB-500 is WADA-banned; KPV is unapproved for any therapeutic use.
- Storage. Refrigerate lyophilized vials and protect from light. After reconstitution, refrigerate and use within four weeks or less, matched to the shortest-lived component.
- Reported side effects. Component literature describes injection-site irritation; GHK-Cu's copper content can cause local discoloration. No controlled safety profile exists for the four-peptide combination.
Sources
- 1.Sikiric P et al. (2018). Brain-gut Axis and Pentadecapeptide BPC 157. Current Neuropharmacology.
- 2.Pickart L, Margolina A (2018). Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. International Journal of Molecular Sciences.
- 3.Goldstein AL et al. (2012). Thymosin β4: a multifunctional regenerative peptide. Expert Opinion on Biological Therapy.
- 4.Dalmasso G et al. (2008). PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology.
- 5.FDA 503A Bulk Drug Substances list — Category 2 (November 2023, BPC-157).